Free Trial

InMode Q3 2023 Earnings Report

InMode logo
$17.08 -0.11 (-0.64%)
(As of 12/20/2024 05:40 PM ET)

InMode EPS Results

Actual EPS
$0.54
Consensus EPS
$0.53
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

InMode Revenue Results

Actual Revenue
$123.11 million
Expected Revenue
$123.00 million
Beat/Miss
Beat by +$110.00 thousand
YoY Revenue Growth
N/A

InMode Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

AI breakthrough about to upend industry (Ad)

Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

I urge you to watch it now.

InMode Earnings Headlines

Analysts Set InMode Ltd. (NASDAQ:INMD) Price Target at $22.60
AI breakthrough about to upend industry
Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.
See More InMode Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InMode? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InMode and other key companies, straight to your email.

About InMode

InMode (NASDAQ:INMD) designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

View InMode Profile

More Earnings Resources from MarketBeat

Upcoming Earnings